Hexima Limited

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 08:34:04 2024-05-01 pm EDT			5-day change	1st Jan Change
0.011 ^AUD	0.00%		0.00%	-38.89%

Mar. 22	Hexima Secures R&D Tax Rebate for Fiscal Year 2023	MT
Mar. 19	Hexima Changes Address	MT

Hexima Limited Announces Board Changes

December 04, 2022 at 04:40 pm EST

Hexima Limited announced the following board changes: The removal of Mr. Michael Aldridge as a director; The removal of Mr. Jake Nunn as a director; and the removal of Mr. Scott Robertson as a director.

Latest news about Hexima Limited

Hexima Secures R&D Tax Rebate for Fiscal Year 2023	Mar. 21	MT
Hexima Changes Address	Mar. 19	MT
Hexima Limited Announces Change of Address	Mar. 19	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director	Nov. 29	CI
Hexima Limited Appoints Phillip Hains as A Non-Executive Director	23-09-18	CI
Hexima Limited Appoints Geoffrey Kempler as Managing Director	23-09-05	CI
Hexima Limited Announces Executive Changes	23-09-05	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director	23-05-11	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Hexima Limited Declares Voting Results	23-01-30	CI
Arovella Therapeutics Appoints COO	23-01-03	MT
Hexima Acting CEO to Step Down	22-12-22	MT
Nicole Van Der Weerden to Step Down as CEO of Hexima Limited	22-12-22	CI
Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office	22-12-14	MT
Hexima Limited Receives Requisition Notice from Merchant Biotech Fund	22-12-13	CI
Hexima Limited Announces Board Changes	22-12-04	CI
10,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	22-11-30	CI
6,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	22-11-30	CI
Hexima Limited Announces Change of Address	22-09-12	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Hexima Managing Director, CEO Steps Down	22-08-02	MT
Hexima Limited Announces Management Changes	22-08-01	CI
Hexima Limited Announces Phase II Results of Pezadeftide	22-07-10	CI

Chart Hexima Limited

Duration

Period

More charts

Company Profile

Hexima Limited is an Australia-based company. The Company is exploring opportunities for transactions with third parties which could enable the potential value of the Companyâs assets, including its intellectual property and other intangible assets, to be realized.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HEXIMA LIMITED	-38.89%	1.2M
MODERNA, INC.	+26.28%	48.09B
IQVIA HOLDINGS INC.	-3.99%	40.43B
LONZA GROUP AG	+46.85%	40.62B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B
BIO-TECHNE CORPORATION	-2.02%	11.88B

Other Biotechnology & Medical Research